首页 | 本学科首页   官方微博 | 高级检索  
检索        


The time-varying cardiovascular benefits of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus: Evidence from large multinational trials
Authors:Salil V Deo MD  Shayan Marsia MBBS  David A McAllister MD  Yakov Elgudin MD  Naveed Sattar MD  Jill P Pell MD
Institution:1. Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK;2. Department of Internal Medicine, Dow Medical College, Karachi, Pakistan;3. Surgical Services, Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, USA

Case School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA;4. Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK

Abstract:
Keywords:cardiovascular outcomes trials  clinical trials  GLP receptor agonist  systematic review  type II diabetes mellitus
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号